TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07869043: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA

Sponsor: Pfizer · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 1100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07869043 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07869043 Rescue Dossier →